GleamWall
中文EN

KRSA Korsana Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1755237 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-264.6%
TTM EPS YoY169.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-42.2%
ROA-33.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets9.9%
Debt / equity0.00x
Current ratio10.42x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.65x
Accruals ratio-11.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q2*2026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue—$0$0$1.02M$875,000$93,000$81,000$1.81M
R&D expense$42,139$0$730,000$519,000$20,479$56,000$36,000$56,000
SG&A expense$6,135$1.77M$2.48M$1.34M$1,478$1.71M$1.50M$1.25M
Operating income-$48,274-$1.77M-$3.21M-$838,000-$21,957-$1.67M-$1.46M$502,000
Income tax$0——$0$0———
Net income-$46.42M-$17.36M-$13.51M-$799,000-$21.72M-$152,000-$73,000$530,000
EPS (basic)-3.19-0.41-0.76—-39.49-0.11-0.56—
EPS (diluted)-3.19-0.41-0.76—-39.49-0.11-0.56—
Weighted avg. shares (diluted)13.53M4.25M4.21M—550,0613.07M2.56M—
Balance sheet
Cash & equivalents$456.22M$1.39M$2.82M$154.13M$163.88M$3.01M$3.64M$10.11M
Receivables—$0$0$1.00M$100,000$525,000$581,000$556,000
Current assets$460.65M$1.51M$3.09M$154.60M$5.07M$4.02M$4.50M$4.22M
PP&E, net$367,000$66,000$66,000$0$0$0$0$0
Total assets$462.08M$6.93M$8.51M$154.60M$10.41M$9.37M$9.85M$9.57M
Current liabilities$44.20M$1.84M$1.71M$12.49M$877,000$800,000$1.07M$725,000
Total liabilities$45.56M$1.84M$1.71M$13.03M$877,000$800,000$1.07M$725,000
Shareholders' equity$391.56M-$63.28M-$47.03M-$33.97M-$21.84M-$123,000$16,000$66,000
Shares outstanding45.54M4.26M4.24M1.24M3.70M3.08M3.06M2.55M
Cash flow statement
Operating cash flow-$46.83M-$1.43M-$1.18M-$1.58M-$264,000-$503,000-$968,000$360,000
Capital expenditure$231,000$0$66,000—$0$0$0—
Free cash flow-$47.06M-$1.43M-$1.24M—-$264,000-$503,000-$968,000—
Investing cash flow-$231,000$0-$66,000—$0$0$0$0
Financing cash flow$351.10M$0$825,000$251,000$1.83M-$130,000$1.38M$0
Stock-based compensation$15.23M$51,000$58,000$95,000$209,000$114,000$114,000$122,000

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.